The two have nine hours to get the rent money in a brash situational comedy that's really a skewed portrait of a community. In “One of Them Days,” Dreux (Palmer), who works as a waitress in a ...

WASHINGTON, Jan 15 (Reuters) - U.S. consumer prices increased by the most in nine months in December amid higher costs for energy goods, pointing to still-elevated inflation that aligns with the ...

Swiss IoT module maker u-blox is to phase out its loss-making cellular IoT business, the firm has said. The division has over 200 employees; jobs are expected to go with its closure. It made revenue ...

Consumer spending will play a large role in the economy in 2025, as it always does. However, the impact has often been overstated. Nonetheless, the strong footing of households—in the aggregate ...

It looks like T-Mobile is now accepting customers into the free beta program for SpaceX’s cellular Starlink service—but only if you have the latest Samsung handsets. On Tuesday, a number of T ...

The world's biggest gathering of humans is also a much-awaited event for India's consumer businesses. In fact, the Kumbh is the most visible part of a big driver of India's economy, the festival cycle ...

(AP Photo/Ted Shaffrey, File) Updated [hour]:[minute] [AMPM] [timezone], [monthFull] [day], [year] Johnson & Johnson will spend more than $14 billion to delve further into the treatment of central ...

Mario Tama / Getty Images Shares of Intra-Cellular Therapies jumped Monday morning after Johnson & Johnson announced plans to buy the biopharmaceutical company. Intra-Cellular shareholders will ...

Initial data for the Heart-2 Phase 1b clinical trial of VERVE-102 targeting PCSK9 expected in second quarter of 2025 Dosing in the Heart-2 trial has moved to the 0.6 mg/kg cohort VERVE-301 ...

Johnson & Johnson has opened the J.P. Morgan Healthcare Conference with a bang, buying out Intra-Cellular Therapies for $14.6 billion. At $132 per share, J&J paid a 39% premium on Friday’s ...

(RTTNews) - Johnson & Johnson (JNJ) and Intra-Cellular Therapies, Inc. (ITCI) announced Monday that they have entered into a definitive agreement under which Johnson & Johnson will acquire all ...

BOSTON, Jan. 13, 2025 (GLOBE NEWSWIRE) -- Verve Therapeutics, a clinical-stage company developing a new class of genetic medicines for cardiovascular disease, today highlighted its recent pipeline ...